...
首页> 外文期刊>MBio >Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
【24h】

Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?

机译:不断发展的抗药性抗生素:天然产品开发的潜在平台?

获取原文

摘要

To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets—have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in Actinobacteria in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery.
机译:为了避免抗生素耐药性危机,我们需要以与耐药性进化速度相匹配的速度开发抗生素。然而,事实证明,由抗生素执行的复杂功能(例如结合膜的渗透,抵抗机制的相互作用以及与分子靶标的相互作用)很难用当前的药物开发方法实现,包括基于靶标的筛选和合理的设计。在这里,我们认为我们可以在实验室中通过抗生素的进化来应对临床中耐药性的进化。基于对一般微生物尤其是放线菌中细菌产生的实验进化研究的结果,我们提出了进化抗生素以规避耐药性机制的方法。这利用了进化的能力,无需设计即可找到复杂问题的解决方案。我们回顾了对这种方法至关重要的进化论,并认为它是可行的,并且比目前的抗生素发现方法具有重要的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号